Physician Resources: Biologics and Novel Therapeutics For Chronic Rhinosinusitis
Upon completion of this activity, participants should be able to:
- Recognize biologic therapies for chronic Rhinosinusitis and current options for treatment
- Identify how to manage patients with refractory chronic rhinosinusitis
- Recall patient outcomes with potential biologic therapies for patients with concomitant asthma and chronic rhinosinusitis
Dr. Stella E. Lee has financial interests with the following entity or entities producing health care goods or services as indicated below:
- Grant/Research Support: Knopp Biosciences, Sanofi Aventis, Regeneron, Allakos Inc.
- Consultant: Sanofi Aventi
All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits ™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.05) continuing education units (CEU) which are equivalent to .50 contact hour.
- 0.50 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 0.50 Attendance